Medindia
Medindia LOGIN REGISTER
Advertisement

FDA Approves Optimer's DIFICID™ (fidaxomicin) Tablets for the Treatment of Patients with Clostridium difficile-Associated Diarrhea (CDAD)

Saturday, May 28, 2011 General News
Advertisement
- In two CDAD clinical trials, DIFICID was non-inferior to vancomycin in clinical response at the end of therapy and superior to vancomycin in sustained clinical response 25 days post-treatment -
Advertisement

Contacts:

Optimer Pharmaceuticals, Inc.

John D. Prunty, Chief Financial Officer & Senior Vice President, Finance

858-909-0736

Canale Communications, Inc.

Jason I. Spark, Senior Vice President

619-849-6005

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close